Skip to main content
Jonathan M Loree on Muck Rack

Jonathan M Loree

As seen in: Nature, Wiley Online Library, BMJ Oncology, BMJ Open, Educational Studies, MDPI, The BMJ, JAMA Oncology, Cancer Discovery, Texas Medical Center and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jonathan M

Contact Jonathan M, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma | Nature Communications

|
By Daniel Renouf, James Topham, Jonathan M Loree, David Schaeffer, Jennifer J. Knox, Petr Kavan, Derek J Jonker, Stephen R Welch, Félix Couture, Mustapha Tehfé, Yoo-Joung Ko, Patricia Tang, Ravi Ramjeesingh, Brandon Meyers, Christina Kim, Pan Du, Sharlene Gill, Dongsheng Tu, Chris O’Callaghan, Frederic Lemay, Mohammed Harb, Nathalie Aucoin, Shidong Jia, Joanna M. Karasinska
| Nature Verified
Abstract The CCTG PA.7 study was a randomized phase II trial comparing chemotherapy with and without dual immune checkpoint inhibition in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Open in Who Shared Issue with article?

Population‐Based Case-Control Study of Antidepressants in Early and Average‐Age Onset Colorectal Cancer: The Impact of Exposure Window, Class, Dose, and Intensity - Cheng - 2026 - Pharmacoepidemiology and Drug Safety - Wiley Online Library

|
By Vicki A. Cheng, Eric C Sayre, Vienna Cheng, Jonathan M Loree
| Wiley Online Library Verified
1 Introduction Antidepressants, categorized into drug classes with distinct mechanisms of action, are widely used in the general population [1, 2] and in individuals with cancer [3, 4] to treat various disorders, including insomnia [5], chronic pain [6], anxiety, and depression [7].
Open in Who Shared Issue with article?

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial - Nature Medicine

|
By Jeanne Tie, Jonathan M Loree, Rachel Wong, James Lynam, Belinda Lee, Lorraine A. Chantrill, Sharlene Gill, Chetan Bettegowda, Nicholas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Siavash Foroughi
| Nature Verified
Abstract Adjuvant chemotherapy in stage III colon cancer provides uncertain benefit at the individual level. Circulating tumor DNA (ctDNA) may help refine risk-adjusted treatment selection. In this multicenter, randomized, phase 2/3 trial, patients with stage III colon cancer underwent ctDNA testing 5–6 weeks after surgery and were assigned (1:1) to ctDNA-guided or standard management.
Open in Who Shared Issue with article?
See all 25 articles